Literature DB >> 25624334

Eravacycline (TP-434) is active in vitro against biofilms formed by uropathogenic Escherichia coli.

Trudy H Grossman1, William O'Brien2, Kathryn O Kerstein2, Joyce A Sutcliffe2.   

Abstract

Eravacycline (formerly TP-434) was evaluated in vitro against pre-established biofilms formed by a uropathogenic Escherichia coli strain. Biofilms were eradicated by 0.5 μg/ml eravacycline, which was within 2-fold of the MIC for planktonic cells. In contrast, colistin and meropenem disrupted biofilms at 32 and 2 μg/ml, respectively, concentrations well above their respective MICs of 0.5 and 0.03 μg/ml. Gentamicin and levofloxacin eradicated biofilms at concentrations within 2-fold of their MICs.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25624334      PMCID: PMC4356792          DOI: 10.1128/AAC.04967-14

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  17 in total

Review 1.  Riddle of biofilm resistance.

Authors:  K Lewis
Journal:  Antimicrob Agents Chemother       Date:  2001-04       Impact factor: 5.191

Review 2.  Bacterial biofilms: a common cause of persistent infections.

Authors:  J W Costerton; P S Stewart; E P Greenberg
Journal:  Science       Date:  1999-05-21       Impact factor: 47.728

3.  Intracellular bacterial biofilm-like pods in urinary tract infections.

Authors:  Gregory G Anderson; Joseph J Palermo; Joel D Schilling; Robyn Roth; John Heuser; Scott J Hultgren
Journal:  Science       Date:  2003-07-04       Impact factor: 47.728

Review 4.  Survival strategies of infectious biofilms.

Authors:  C A Fux; J W Costerton; P S Stewart; P Stoodley
Journal:  Trends Microbiol       Date:  2005-01       Impact factor: 17.079

5.  Differentiation and distribution of colistin- and sodium dodecyl sulfate-tolerant cells in Pseudomonas aeruginosa biofilms.

Authors:  Janus A J Haagensen; Mikkel Klausen; Robert K Ernst; Samuel I Miller; Anders Folkesson; Tim Tolker-Nielsen; Søren Molin
Journal:  J Bacteriol       Date:  2006-10-13       Impact factor: 3.490

Review 6.  Evolving concepts in biofilm infections.

Authors:  Luanne Hall-Stoodley; Paul Stoodley
Journal:  Cell Microbiol       Date:  2009-04-06       Impact factor: 3.715

7.  Tetracycline rapidly reaches all the constituent cells of uropathogenic Escherichia coli biofilms.

Authors:  G Stone; P Wood; L Dixon; M Keyhan; A Matin
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

8.  Persister cells and tolerance to antimicrobials.

Authors:  Iris Keren; Niilo Kaldalu; Amy Spoering; Yipeng Wang; Kim Lewis
Journal:  FEMS Microbiol Lett       Date:  2004-01-15       Impact factor: 2.742

9.  The application of biofilm science to the study and control of chronic bacterial infections.

Authors:  William Costerton; Richard Veeh; Mark Shirtliff; Mark Pasmore; Christopher Post; Garth Ehrlich
Journal:  J Clin Invest       Date:  2003-11       Impact factor: 14.808

10.  In vitro and in vivo activities of levofloxacin against biofilm-producing Pseudomonas aeruginosa.

Authors:  H Ishida; Y Ishida; Y Kurosaka; T Otani; K Sato; H Kobayashi
Journal:  Antimicrob Agents Chemother       Date:  1998-07       Impact factor: 5.191

View more
  10 in total

Review 1.  Investigational antimicrobial agents of 2013.

Authors:  Michael J Pucci; Karen Bush
Journal:  Clin Microbiol Rev       Date:  2013-10       Impact factor: 26.132

Review 2.  Antibiotics in the clinical pipeline at the end of 2015.

Authors:  Mark S Butler; Mark At Blaskovich; Matthew A Cooper
Journal:  J Antibiot (Tokyo)       Date:  2016-06-29       Impact factor: 2.649

3.  In vitro susceptibility of β-lactamase-producing carbapenem-resistant Enterobacteriaceae (CRE) to eravacycline.

Authors:  Yunliang Zhang; Xiaoyan Lin; Karen Bush
Journal:  J Antibiot (Tokyo)       Date:  2016-06-29       Impact factor: 2.649

Review 4.  Eravacycline, a newly approved fluorocycline.

Authors:  Young Ran Lee; Caitlin Elizabeth Burton
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-06-07       Impact factor: 3.267

5.  [New antibiotics for severe infections due to multidrug-resistant pathogens : Definitive treatment and escalation].

Authors:  D C Richter; T Brenner; A Brinkmann; B Grabein; M Hochreiter; A Heininger; D Störzinger; J Briegel; M Pletz; M A Weigand; C Lichtenstern
Journal:  Anaesthesist       Date:  2019-11       Impact factor: 1.041

Review 6.  Review of Eravacycline, a Novel Fluorocycline Antibacterial Agent.

Authors:  George G Zhanel; Doris Cheung; Heather Adam; Sheryl Zelenitsky; Alyssa Golden; Frank Schweizer; Bala Gorityala; Philippe R S Lagacé-Wiens; Andrew Walkty; Alfred S Gin; Daryl J Hoban; James A Karlowsky
Journal:  Drugs       Date:  2016-04       Impact factor: 9.546

7.  Pharmacodynamics of Moxifloxacin, Meropenem, Caspofungin, and Their Combinations against In Vitro Polymicrobial Interkingdom Biofilms.

Authors:  Albert Ruiz-Sorribas; Hervé Poilvache; Françoise Van Bambeke
Journal:  Antimicrob Agents Chemother       Date:  2021-12-20       Impact factor: 5.938

8.  Activity of Eravacycline against Escherichia coli Clinical Isolates Collected from U.S. Veterans in 2011 in Relation to Coresistance Phenotype and Sequence Type 131 Genotype.

Authors:  James R Johnson; Stephen B Porter; Brian D Johnston; Paul Thuras
Journal:  Antimicrob Agents Chemother       Date:  2015-12-14       Impact factor: 5.191

9.  A steam-based method to investigate biofilm.

Authors:  Jason Tasse; Andréa Cara; Maude Saglio; Régis Villet; Frédéric Laurent
Journal:  Sci Rep       Date:  2018-08-29       Impact factor: 4.379

Review 10.  Treatment for carbapenem-resistant Enterobacterales infections: recent advances and future directions.

Authors:  Kathleen Tompkins; David van Duin
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2021-06-24       Impact factor: 5.103

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.